Hospital Universitario Principe De Asturias
- Address
- lock Available on a paid plan
Endocrinology and Nutrition Research at Hospital Universitario Principe De Asturias
The clinical trial activity at this site focuses on nutritional and metabolic diseases, with particular attention to type 2 diabetes, obesity, and overweight. These studies are aimed at evaluating new treatment options and understanding how better therapies may improve blood sugar control and support weight management in people with metabolic conditions.
- Testing a new therapy for type 2 diabetes in people with obesity or overweight
- Assessing treatment effectiveness and safety in metabolic disease
- Exploring better ways to support long-term care in endocrinology and nutrition
With a small but focused portfolio, the site contributes to research that may help improve everyday management of chronic metabolic disorders.
Hemic and Lymphatic Diseases Research
Another key area of research involves hemic and lymphatic diseases, especially follicular lymphoma. The trials in this field are designed to study the safety and effectiveness of new treatment approaches for adults with untreated lymphoma, with the goal of improving response to therapy and expanding options for cancer care.
- Evaluating a new treatment approach for follicular lymphoma
- Comparing cancer therapy effectiveness against standard treatment options
- Studying safety and tolerability in hematologic oncology
At Hospital Universitario Principe De Asturias, this research supports progress in lymphoma treatment by examining whether newer therapies can offer better outcomes for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 56 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Fundacion PETHEMA2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fundacion PETHEMA2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario Principe De Asturias
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 56 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 2 | Unknown | 2020-11-23 | 2024-01-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.